Aclaris Therapeutics, Inc. (ACRS)

Market Cap	174.33M
Revenue (ttm)	17.78M
Net Income (ttm)	-130.21M
Shares Out	108.28M
EPS (ttm)	-1.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	650,344
Open	1.610
Previous Close	1.590
Day's Range	1.580 - 1.630
52-Week Range	1.050 - 5.170
Beta	0.39
Analysts	Strong Buy
Price Target	9.25 (+474.53%)
Earnings Date	Aug 6, 2025

About ACRS

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatmen...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 7, 2015
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: ACRS
• Website: https://www.aclaristx.com

Financial Performance

In 2024, Aclaris Therapeutics's revenue was $18.72 million, a decrease of -40.09% compared to the previous year's $31.25 million. Losses were -$132.07 million, 49.3% more than in 2023.

Analyst Summary

According to 9 analysts, the average rating for ACRS stock is "Strong Buy." The 12-month stock price target is $9.25, which is an increase of 474.53% from the latest price.

Price Target

$9.25

(474.53% upside)

Analyst Consensus: Strong Buy